Finance

Lists
0PQ:FRA
ProQR Therapeutics NV
€1.81
+1.34%
(+0.024) 1D
Sep 3, 8:01:02 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 0PQ...
Open
€1.81
High
€1.81
Low
€1.81
Mkt. cap
303.41M
Avg. vol.
23.00
Volume
0.00
52-wk high
€2.56
52-wk low
€1.14
No. of employees
187
Open
€1.81
High
€1.81
Low
€1.81
Mkt. cap
303.41M
Avg. vol.
23.00
Volume
0.00
52-wk high
€2.56
52-wk low
€1.14
No. of employees
187
Profile
ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer. Wikipedia
About ProQR Therapeutics NV
CEODaniel A. de Boer
Employees187
Founded2012
Headquarters-
SectorBiotechnology
Websiteproqr.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.92M
4.72M
2.03M
8.76M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11.08M
9.92M
11.83M
12.67M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.12M
3.89M
3.85M
4.91M
Operating expense
14.20M
13.81M
15.68M
17.58M
Total operating expenses
14.20M
13.81M
15.68M
17.58M
Operating income
-11.28M
-9.10M
-13.65M
-8.82M
Other non operating income
-2.00K
59.00K
54.00K
-33.00K
EBT including unusual items
-11.01M
-8.92M
-13.38M
-8.70M
EBT excluding unusual items
-11.01M
-8.92M
-13.38M
-8.70M
Income tax expense
-
1.00K
-
25.00K
Effective tax rate
-
-0.01%
-
-0.29%
Other operating expenses
-
-
-
-
Net income
-11.01M
-8.92M
-13.38M
-8.73M
Net profit margin
-377.56%
-189.14%
-658.29%
-99.65%
Earnings per share
-
-
-
-
Interest and investment income
280.00K
1.41M
212.00K
152.00K
Interest expense
-
-929.00K
-
-
Net interest expenses
280.00K
477.00K
212.00K
152.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.61M
-8.87M
-12.96M
-8.12M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps